Early detection of cardiovascular-renal-metabolic conditions: from silent to seen

​Join us for an enriching discussion on curbing the significant burden of cardiovascular-renal-metabolic (CRM) conditions.

​Building on recent and upcoming global commitments on these interconnected conditions, the session will explore practical actions for countries to drive integrated CRM care for patients. There will be a particular focus on improving early screening and diagnosis of chronic kidney disease (CKD) and steatotic liver disease (SLD), which are often silent until advanced stages and co-exist with and amplify other CRM conditions.

​This session on the sidelines of the World Health Assembly in Geneva will bring together perspectives from the advocacy sector, academia, governments, and industry.

​Our expert panel will discuss topics such as:

• ​What it will take to scale up early screening and detection of CRM conditions

• ​The barriers and opportunities for improved care for CRM conditions

• ​How global commitments, including on CKD, SLD and other areas can be implemented in an integrated way for long-term impact

​Speakers will include:

• ​Daniel Gallego – President, European Kidney Patient's Federation

• ​Neil Johnson - Executive Director, Global Heart Hub

• ​Richard Sloggett - Founder and Programme Director, Future Health Research

• ​Sandy Sommer - Corporate Senior Vice President, Head of Therapeutic Area Cardiovascular, Renal & Metabolic, Boehringer Ingelheim

​This event is organized by Boehringer Ingelheim - please click here to check out all of our events at the 79th World Health Assembly